Stalevo Related Published Studies
Well-designed clinical trials related to Stalevo (Carbidopa / Levodopa / Entacapone)
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2009.03.15]
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
Well-designed clinical trials possibly related to Stalevo (Carbidopa / Levodopa / Entacapone)
Factors predictive of the development of Levodopa-induced dyskinesia and
wearing-off in Parkinson's disease. [2013]
Other research related to Stalevo (Carbidopa / Levodopa / Entacapone)
Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED. [2011.02.20]
[The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off]. [2010.07.30]
Levodopa/carbidopa/entacapone in Parkinson's disease. [2009.07]
[Long term experience with Stalevo in Szeged, Hungary] [2009.05.30]
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. [2008.12.03]
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.11]
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.10.31]
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. [2008.10.07]
Should levodopa dose be reduced when switched to stalevo? [2008.03]
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life] [2008.01.30]
Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. [2007]
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). [2006.09]
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. [2006.03]
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. [2005.07]
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. [2005.02]
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). [2004.07]
Levodopa/carbidopa/entacapone (Stalevo). [2004.01.13]
Other possibly related research studies
Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. [2010.03]
|